IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference
21 févr. 2023 07h00 HE
|
IN8bio, Inc
NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
IN8bio to Present at the B. Riley Securities’ 3rd Annual Virtual Oncology Conference
17 janv. 2023 07h00 HE
|
IN8bio, Inc
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today...
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
05 janv. 2023 07h00 HE
|
IN8bio, Inc
All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial...
IN8bio to Present at Biotech Showcase 2023 in San Francisco
03 janv. 2023 07h00 HE
|
IN8bio, Inc
Company to be in San Francisco January 9-11, 2023, during the 41st Annual J.P. Morgan Healthcare Conference NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage...
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
12 déc. 2022 07h00 HE
|
IN8bio, Inc
Results from the first cohort of patients with hematological malignancies show patients remained progression free; ongoing durations of response extend beyond 2.5 years (31.9 months)INB-100 continues...
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
08 déc. 2022 07h00 HE
|
IN8bio, Inc
Phase 2 clinical trial initiation expected in 2023 Company to host conference call to discuss recent clinical updates, including updated data from the Phase 1 clinical trial of INB-100 being...
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
10 nov. 2022 07h30 HE
|
IN8bio, Inc
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual...
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting
03 nov. 2022 09h10 HE
|
IN8bio, Inc
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML).Clinical activity observed includes continuing robust...
IN8bio to Present at November Investor Conferences
01 nov. 2022 07h30 HE
|
IN8bio, Inc
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio to Present at Cantor Oncology & HemOnc Conference
27 sept. 2022 07h30 HE
|
IN8bio, Inc
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...